Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — Henlius — FY2022 Earnings Presentation
48 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, March 2023
Slide 1: 2022 Annual Results Investor Presentation
Henlius(2696.HK) 2022 Annual Results Investor Presentation March 2023 © 2023 Henlius
Slide 2: 2022 Business Highlights & Company Strategy
01 2022 Business Highlights & Company Strategy © 2023 Henlius
Slide 3: 2022 Business Highlights: Revenue Tops 3.21B RMB
2022 Business Highlights:Revenue Tops 3.21B RMB Commercial Operating Revenue BD Pipeline Capacity Cash Flow 3.2B RMB 9 50+ 48KL 1B RMB Commercialization Business Development R&D Manufacturing Financial • Growing core capabilities of • 5 global out-licensing deals • ASTRUM-005 trial endorsed • Songji
Slide 4: Our Mission and Vision
Biosimilars Maximize the commercialization value in China and Our Mission international markets and Vision Innovative Drugs Explore new mechanisms, new technology platforms and Affordable Innovation expand the therapeutic areas Reliable Quality Globalization Becoming a global and scale-up biopharma
Slide 5: Leading Biosimilars Business in China with International Competitiveness
Leading Biosimilars Business in China with International Competitiveness Biosimilars 1 9 2.3 Innovative Drugs Strong Competency of A Pioneer 9 biosimilars products Sales revenue of Biosimilars business Biosimilars Leader biosimilars* in 2022 Globalization in the pipeline, including approved in China
Slide 6: The Global Antibody Biosimilar Market Promising Outlook
The Global Antibody Biosimilar Market Promising Outlook ⚫ Antibody biosimilars account for more than half of the entire biosimilar market. With high potential in regulated markets like EU and the U.S., registration and market access policies also encourage biosimilars Biosimilars ⚫ Chinese biosimila
Slide 7: Sales Revenue of Henlius' Biosimilars Grew Rapidly
Sales Revenue of Henlius' Biosimilars Grew Rapidly ⚫ Successfully launched 4 biosimilars in China and abroad, sales revenue reached 2.34 billion RMB in 2022 Biosimilars ⚫ 5 biosimilars are in the clinical phase, mainly in oncology, osteology, and other therapeutic areas, covering targets such as HER
Slide 8: First Commercialized Innovative Drug — Serplulimab
First Commercialized Innovative Drug — Serplulimab Biosimilars Innovative Drugs 339M 1B Differentiated Globalization RMB RMB Indications Approved Indications: Out-licensing agreement with Remarkable commercialization • MSI-H solid tumor Fosun Pharma to grand exclusive results —sales revenue of 339M
Slide 9: R&D for Novel Drugs: Beyond Oncology, Expanding into New TAs
R&D for Novel Drugs: Beyond Oncology, Expanding into New TAs for UMN Product Type & Introduction Innovative Pipeline Distribution By Stage (By Molecule) Biosimilars ✓ Total 57 molecules in pipeline with 48 innovative drugs 22 ✓ Mainly focuses on oncology pipeline and started to explore around Autoim
Slide 10: R&D Strategy: Targeted Delivery and Conjugates Platform
R&D Strategy: Breakthrough via Targeted Delivery and Conjugates Platform, Accelerate by Deep Data Driven and Biocomputation, and Focus on Metabolism, Immunity, Neurological, Oncology Areas Biosimilars Targeted Drug Delivery Precision and Combo Therapy Innovative Drugs Center around metabolism, Devel
Slide 11: Globalization: Enter into Commercialization Stage
Globalization: Enter into Commercialization Stage Biosimilars Innovative Drugs Globalization Europe US Other Countries & Regions Organon Organon Organon Abbott Trastuzumab approved in Australia, Argentina, Trastuzumab marketed in ~20 European countries Trastuzumab BLA under FDA review Saudi Arabia a
Slide 12: Commercialization
02 Commercialization © 2023 Henlius
Slide 13: HANQUYOU (Trastuzumab): Sales Growth 86.1% YoY, BLA Submitted to FDA
HANQUYOU®(Trastuzumab): Sales Growth 86.1% YoY, BLA Submitted to FDA In Billion International quality Strong sales 1.73 RMB • First approved trastuzumab biosimilar in China 0.93 • First "Chinese nationality" mAb biosimilar approved in 1.73B RMB Europe • BLA submitted to FDA; expected to be the first
Slide 14: Excellent Performance of HANQUYOU
Excellent Performance of HANQUYOU® Sales Per Capita Sales Expenses Ratio Higher cost-effectiveness than domestic innovative biotech companies > 3.7M RMB < 40% Industry Benchmark – Chinese Industry Benchmark – Chinese Biotechs (~1.5M-2M RMB) Biotechs (~57%-62%) • 2 specifications were customized to a
Slide 15: HANSIZHUANG (Serplulimab): Globally First PD-1 mAb for SCLC 1L
HANSIZHUANG®(Serplulimab): Globally First PD-1 mAb for SCLC 1L Treatment Impressive R&D results Differentiated strategies to seize the market • Outstanding clinical data published in top medical • Developed differentiated marketing strategies and journals, including JAMA, Nature Medicine, British fo
Slide 16: HANSIZHUANG Commercialization Highlights
HANSIZHUANG® Commercialization Highlights First-class Commercialization Efficiency Improve Market Share with Differentiation Strategy Outstanding Differentiation Strategy Achievements Focus on SCLC (15-20% of total lung cancer patients) 339M RMB Sales outperformed most of the competing PD- 1/PD-L1 l
Slide 17: HANLIKANG (Rituximab): Strengthen the Leading Market Position
HANLIKANG®(Rituximab): Strengthen the Leading Market Position Acceleration on market access and penetration Commercial Success • Approved in February 2019 as the first approved In Million RMB biosimilar in China as well as the first approved 554M RMB rituximab biosimilars in China 542 554 • Innovati
Slide 18: HANDAYUAN (Adalimumab): Entered Autoimmune Diseases Area
HANDAYUAN® (Adalimumab): Entered Autoimmune Diseases Area Improve patients’ availability and accessibility Work with partners to penetrate the market • Sales of HANDAYUAN® in China executed by Jiangsu Wanbang, 51M RMB • Henlius’ First product for autoimmune diseases • Covered by NRDL in 30 provinces
Slide 19: HANBEITAI (Bevacizumab): Commercialization Start in 2023
HANBEITAI® (Bevacizumab): Commercialization Start in 2023 Acceleration on market access and penetration Exploration for new medication methods • Covered by NRDL in 30 provinces, and completed tendering • The only bevacizumab biosimilars with phase III clinical data for and procurement platform listi
Slide 20: Business Development
03 Business Development © 2023 Henlius
Slide 21: 5 Out-licensing Deals with Total Upfront Payment of 1.5 Billion RMB
5 Out-licensing Deals with Total Upfront Payment of 1.5 Billion RMB • Business footprint: Fosun Pharma USA (NYSE: OGN) 140+ countries & regions • Fosun Pharma: global innovation-driven pharmaceutical Spin-off from • Sustainable operation: and healthcare group MERCK 100+ years • Fosun pharma USA: est
Slide 22: In-licensing Innovative Products & Technology Platforms
In-licensing Innovative Products & Technology Platforms Cooperation for CDx Development & In-licensing AXC Products & Platforms to Enrich Pipeline Commercialization PALLEON NOVACYTE MediLink MEDx • Her2-Sialidase: preclinical study shows • Joint development of no more than 3 ADC • Innovative platfor
Slide 23: Research & Development
04 Research & Development © 2023 Henlius
Slide 24: Product Pipeline
Product Pipeline Pre-clinical IND Phase I Phase II Phase III NDA In-Market HLX61 HLX51 HLX10(1) (serplulimab)+HLX26 HLX10(1) (serplulimab)+HANBEITAI HLX10(1) (serplulimab)+chemo HLX10(1) (serplulimab)+chemo HANSIZHUANG (serplulimab) (1) Undisclosed (tumor immunity) OX40 PD-1+LAG-3 PD-1+VEGF PD-1 PD-
Slide 25: R&D: Milestones for Clinical Pipeline
4.1 R&D: Milestones for Clinical Pipeline © 2023 Henlius
Slide 26: Clinical Pipeline Milestones - 2022 Review
Clinical Pipeline Milestones - 2022 Review 1H2022 2H2022 HLX10 HLX10 HLX02 Extensive stage small cell lung Esophageal squamous cell BLA Submission to FDA cancer (ES-SCLC) carcinoma (ESCC) 1L (CN) 1L (CN) NDA/BLA/MAA Submission HLX10 HLX04-O HLX22 Esophageal squamous cell Wet Age-Related Macular Gast
Slide 27: ASTRUM-005 & ASTRUM-007 Published in JAMA and Nature Medicine
ASTRUM-005 & ASTRUM-007 were Published in JAMA and Nature Medicine Respectively ASTRUM-005: Presented at 2022 ESMO Asia, updated data for 1L ES-SCLC ASTRUM-007: Presented at 2022 CSCO, reported data for 1L EC Data cut-off date: 2022-6-13 Data cut-off date: 2022-4-15 100 100 | | | |||||| || |||||||||
Slide 28: HLX208-LCH/ECD201 Studies Showed Promising Results
HLX208-LCH/ECD201 Studies Showed Promising Results Challenges LCH/ECD is a clonal hematologic malignancy characterized by activating MAPK pathway, which belongs to • Adults LCH/ECD is a rare disease that can affect multiple systems of the inflammatory myeloproliferative neoplasm. whole body and seri
Slide 29: Advancement of Clinical Pipeline (Phase 2/3)
Advancement of Clinical Pipeline (Phase 2/3) Anti-HER2 mAb Anti-EGFR mAb Extracellular Anti- Intracellular VEGF mAb Activate RAS Extracellular Growth Inhibitor Endothelial Cell Intracellular Cell Death Signaling Pathway Signaling Pathway Downstream Signal Downstream Signal Transduction Pathway Trans
Slide 30: Early-Stage Assets (Clinical IND/Phase 1) (1/2)
Early-Stage Assets (Clinical IND/Phase 1) (1/2) Tumor Cell/Antigen- presenting Cell T cell Anti-LAG3 mAb Tumor Cell Tumor Cell T Cell or T Cell or NK Cell NK Cell Antigen- Antigen- presenting Cell presenting Cell or Tumor Cell or Tumor Cell Anti-LAG3 mAb Tumor Cell T/NK Cell HLX51(OX40) HLX53(TIGIT)
Slide 31: Early-Stage Assets (Clinical IND/Phase 1) (2/2)
Early-Stage Assets (Clinical IND/Phase 1) (2/2) Tumor Cell / T/NK Cell, etc. Antigen-presenting Effector T/B/NK Cell Cell, etc. Tumor Cell TGF-β Receptor block c Antigen Anti-PD-1 mAb Effector NK Cell Inhibition of Release Recipient T Cell Anti-GARP mAb T cell Cytotoxic Regulatory T Cell Release Blo
Slide 32: Clinical Pipeline Milestones in 2023
Clinical Pipeline Milestones in 2023 1H2023 2H2023 HLX10 HLX10 Extensive stage small cell lung Non-squamous non-small cancer (ES-SCLC) cell lung cancer (nsNSCLC) 1L (EU) 1L (CN) NDA/BLA/MAA Submission HLX10 HLX208 HLX07 HLX208 HLX301 Non-squamous non-small Metastatic colorectal Esophageal squamous S
Slide 33: R&D: Pre-clinical Progress
4.2 R&D: Pre-clinical Progress © 2023 Henlius
Slide 34: Targeting Clinical Benefits for Unmet Medical Needs
Targeting Clinical Benefits for Unmet Medical Needs, Focus on Tumors, Metabolic, Cardiovascular, Renal and Neurological Disorders Technologies for New Drug R&D: Deep Data Driven Drug Clinical Value-oriented New Drug R&D Discovery and Biocomputation Accelerated Drug Molecule Design (BAMD) Focus on so
Slide 35: Antibody Drug Conjugate (ADC) R&D Strategy
Antibody Drug Conjugate (ADC) R&D Strategy Develop differentiated ADC Increase the efficacy of Improve safety and Enhance the selectivity of Expand the application products: establish a new ADCs: develop Multiple- therapeutic window of ADCs: build Tumor scenarios of ADCs: payload-linker and Payloads
Slide 36: Deep Data and Computation Driven Innovative Drug Development
Deep Data and Computation Driven Innovative Drug Development Targeting Inflammation, Autoimmunity, and Metabolism Based on the Deep Data Driven Drug Discovery Driven by the BAMD platform, design new drug (5D) platform, integrate medical informatic data to molecules such as peptides and nucleic acids
Slide 37: Manufacturing: Capacity Breakthroughs
05 Manufacturing: Capacity Breakthroughs (Strengthen Market Leading Position in Manufacturing Technology & Quality) © 2023 Henlius
Slide 38: Songjiang 1st Plant: 24,000L Capacity Approved for HANQUYOU
Songjiang 1st Plant: 24,000L Capacity Approved for HANQUYOU 24,000L Leading Commercial Manufacturing Capability In China • Total commercial production capacity of Songjiang 1st Plant & Xuhui Total Design Capacity Facility in 2022: 48,000L • Commercial GMP batches: 582+(since 2019) 144,000L Xuhui Sit
Slide 39: Total Capacity Estimated to Reach 144,000L by 2026
Total Capacity Estimated to Reach 144,000L by 2026 Total Total Production Capacity Planning Capacity (L) 160000 144000 120000 84000 80000 48000 40000 20000 24000 • Building 3 Capping 0 2020 2021 2022 2023 2024 2025 2026 2027 Xuhui Facility Songjiang 1st Plant Songjiang 2nd Plant N: (5+1)*2 KL (6*2 K
Slide 40: Operation Excellence to Improve Efficiency and Reduce Costs
Operation Excellence to Improve Efficiency and Reduce Costs Lean Operations Localization Continuous Process Improvement 2021 2023 Lead Time -67% 20% A 2020 2022 -20% -70% B C -85% Productivity Production Cycle • Improve company policies, establishing culture of • High efficiency and stable domestic
Slide 41: 2022 Financial Review
06 2022 Financial Review © 2023 Henlius
Slide 42: 2022 Fiscal Year Revenue Tops RMB 3.21B, YoY Growth 91.1%
2022 Fiscal Year Revenue Tops RMB 3.21B, YoY Growth 91.1% Revenue Product Income 2022 Revenue Breakdown (in Million RMB) (in Million RMB) 3,214.7 2,675.4 79.0% BD & Others HANLIKANG 91.1% 17% 17% 1,682.5 251.3% 1,494.6 HANSIZHUANG 186.3% 10% HANQUYOU 587.6 438.9% HANDAYUAN 546.2% 425.5 54% 90.9 79.0
Slide 43: 2022 Net Loss Narrowed; Positive Operating CF Generated
2022 Net Loss Narrowed; Positive Operating CF Generated Net Loss Excl. Extraordinary Items Narrowed Total R&D Costs: the portion of R&D costs (in Million RMB) expensed increased on income statement (in Million RMB) 2019 2020 2021 2022 0.0 0.0% 2,183.2 -49.2% -16.3% 1,763.7 -200.0 -500.0% 1,710.9 -16
Slide 44: Financial Highlights
Financial Highlights Financial Data (Selected) 2022 2021 YOY Growth Unit: In million RMB % of revenue In million RMB % of revenue % Revenue 3,214.7 100.0% 1,682.5 100.0% 91.1% Product sales 2,675.4 83.2% 1,494.6 88.8% 79.0% BD and other revenue 539.4 16.8% 187.8 11.2% 187.2% Cost of sales (844.6) (2
Slide 45: 2023 Performance Outlook
07 2023 Performance Outlook © 2023 Henlius
Slide 46: Our Goals for 2023
Our Goals for 2023 Revenue: rapid growth driven by strong market demands of HANSIZHUANG® and HANQUYOU® Profitability: improve P&L level and maximize growth from within Cashflow: positive OCF generated for the past two years; strengthen organic growth in 2023 and build strong and healthy cash flows R
Slide 47: Disclaimer
声明 Disclaimer • 复宏汉霖、陈述人或提供人对本文件内容(文件内容亦有可能包括前瞻性陈述)均不做出明示或默示的保证、声明或陈述(包括但不限于:本内容针对为任意特定目的而关于内容 所具有的及时性、通用性、精确性的声明,或者关于使用本文件内容所获得信息无误可信的声明)。如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复宏汉霖、陈 述人或提供人对此不承担责任。 • 本文件及其中所包含内容的所有权利包括版权均由复宏汉霖独家所有,其中相关的“Henlius” 和“复宏汉霖”字样、图案及相关LOGO标识均为复宏汉霖合法所有的字号、商标 和标识。未经复宏汉霖书面同意,任何第三方不得以包括
Slide 48: © 2023 Henlius
Q | Henlius #225 ARENA Sia Mio Reliable Quality Affordable Innovation